A day after the China ban, the U.S. reintroduced an amended version of the SARMS Control Act of 2018 to classify SARMS as a Schedule III controlled substance.
But, this act is a long way from being passed:
Introduced on Nov 19, 2019
This bill is in the first stage of the legislative process. It was introduced into Congress on November 19, 2019. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Prognosis: 4% chance of being enacted according to Skopos Labs
Essentially, the Bill was (re)introduced in November. Even "if" it passes the Committee, it will still need to pass the House... then the Senate... then the President.
Reference: https://www.govtrack.us/congress/bills/116/s2895With the pending scarcity of raws available, a market price increase wouldn't surprise me the least bit, but I think the ban of above-board SARM sales is a good ways off.